| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Trinity Biotech plc$0.59
+0.02 (+3.51%)
F 10Pipeline Score MedTech · Pre-Clinical
Market Cap
11.64 M
EPS
-2.02
P/E Ratio
-
Value Trade
96.35 K
3.79 %
Week
-12.75 %
1 Month
-18.1 %
3 Month
-32.28 %
6 Month
-96.34 %
5 Year
-99.31 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
64.25 K
52 Week Range
0.50 - 3.44
% held by Insiders
3.57 %
% held by Institutions
5.55 %
Enterprise Value
144.49 M
Total Shares
19.34 M
Short %
1.29 %
Float Shares
18.65 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 834 of 905)
Percentile RankTrinity Biotech plc has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EpiCapture | Prostate cancer | Phase 2 | 2025-11-17 | |||
EpiCapture | Prostate cancer | Phase 2 | 2025-11-17 | |||
EpiCapture | Prostate cancer | Phase 2 | 2025-11-17 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TRIB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Trinity Biotech plc (TRIB) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TRIB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRIB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRIB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRIB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TRIB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TRIBTrinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
Trinity Biotech announced successful clinical results for its enhanced EpiCapture prostate cancer test, which uses machine learning to improve risk prediction accuracy. The test demonstrated an impressive clinical accuracy of 85% in a study involving 750 diverse patient samples. The company plans to commercialize the test through its New York laboratory, marking a significant step into precision oncology.
Read more →TRIBTrinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
Trinity Biotech has partnered with the University at Buffalo to develop and commercialize biomarkers for Sjögren's Syndrome, a commonly underdiagnosed autoimmune disease. This collaboration aims to enhance diagnostic accuracy and speed, addressing significant unmet clinical needs. The initiative is part of Trinity's strategy to expand its specialty diagnostic offerings in the U.S. market.
Read more →TRIBTrinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
Trinity Biotech has initiated the commercial rollout of its next-generation HbA1c column system in Brazil after receiving regulatory approval. The Premier Hb9210 platform, now the only HbA1c system to achieve IFCC Gold classification for 2026, aims to enhance diabetes management in a country with a large diabetes population. The company has also appointed Bruna Gigliotti to lead its Brazilian operations, anticipating increased adoption of the new system.
Read more →TRIBTrinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
Trinity Biotech has entered into a $25 million Standby Equity Purchase Agreement with Yorkville Advisors to enhance its commercialization and R&D efforts. The financing aims to support the company's growth, particularly in HIV testing and the development of its next-generation glucose monitoring platform, CGM+. The company anticipates continued operational progress into 2026.
Read more →TRIBTrinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation
Trinity Biotech has secured regulatory approval to commence upstream manufacturing of its Uni-Gold™ HIV rapid test. This approval allows the company to implement an offshore and outsourced production model, enhancing cost efficiency and scalability. The move is part of Trinity's Comprehensive Transformation Plan aimed at improving financial performance and market reach.
Read more →TRIBTrinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
Trinity Biotech has announced that its Premier Hb9210™ HbA1c Analyser has received the prestigious IFCC Gold Classification for 2026, marking it as the only system globally to achieve this recognition. This milestone underscores the company's commitment to innovation in diabetes care. The new Buffer A Plus column system enhances usability and reduces costs while maintaining high patient care standards. Trinity Biotech's executives will showcase these advancements at the World Health Expo in February 2026.
Read more →TRIBTrinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
Trinity Biotech has entered into agreements with Perceptive Advisors to enhance its capital structure and financial flexibility. These arrangements aim to support the company's growth initiatives, particularly in diabetes management and diagnostics. The agreements also extend the maturity of the credit agreement to early 2027, allowing for continued investment in strategic priorities.
Read more →TRIBTrinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances
Trinity Biotech has secured regulatory clearances for its high-capacity HbA1c column system, enabling its rollout in over 10 countries, including the U.S. This advancement enhances testing efficiency and supports recurring revenue opportunities. The global HbA1c market is projected to grow significantly, positioning Trinity Biotech favorably in the diabetes management sector.
Read more →TRIBTrinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation
Trinity Biotech has secured World Health Organization approval for the offshored manufacturing of its Uni-Gold HIV test. This regulatory milestone is part of a broader transformation plan aimed at improving profitability and operational efficiency. The company plans to implement this new manufacturing model in the coming months, which is expected to enhance gross margins and cash flow.
Read more →TRIBTrinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
Trinity Biotech has announced a strategic collaboration with a bioinformatics company to enhance the EpiCapture prostate cancer test, which utilizes DNA methylation patterns for non-invasive monitoring. This collaboration aims to support the test's progression towards regulatory approval and commercialization. The EpiCapture test has shown potential in accurately predicting high-grade prostate cancers, which could improve patient outcomes and reduce invasive procedures.
Read more →TRIBTrinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
Trinity Biotech has welcomed a proposal from its largest investor, Perceptive Advisors, to convert part of its outstanding debt into equity. This strategic move is expected to strengthen the company's balance sheet and improve financial flexibility, supporting its growth objectives. Discussions are anticipated to align with stakeholder interests.
Read more →TRIBTrinity Biotech Regains Compliance with Nasdaq Listing Requirements
Trinity Biotech plc has announced that it has regained compliance with Nasdaq's minimum bid price and market value requirements. This follows a period of non-compliance earlier in the year. The company has demonstrated a closing bid price of $1.00 per share or greater and a market value of publicly held shares exceeding $15 million. However, future compliance is uncertain.
Read more →TRIBTrinity Biotech Appoints Paul Tivnan as Non-Executive Director
Trinity Biotech has appointed Paul Tivnan as a Non-Executive Director to its Board. With over 25 years of experience in finance and corporate governance, Tivnan's expertise is expected to aid the company's growth in diagnostics and wearable health technologies. His appointment aligns with Trinity's strategy to strengthen corporate governance.
Read more →TRIBRegulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
Trinity Biotech has received regulatory approval to commence offshore and outsourced manufacturing of its TrinScreen™ HIV rapid test. This strategic move is expected to enhance scalability, reduce fixed costs, and improve gross margins. The transition marks a significant milestone in the company's transformation strategy, aiming for long-term financial health.
Read more →TRIBTrinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service
Trinity Biotech has received regulatory approval from the New York State Department of Health to launch its FDA-cleared PreClara™ Ratio biomarker test for assessing preeclampsia risk. This test aims to provide critical insights for clinicians managing hypertensive disorders in pregnant women. The service is expected to roll out in Q3 2025, marking a significant advancement in maternal health diagnostics.
Read more →TRIBTrinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor
Trinity Biotech announced significant clinical trial results for its redesigned CGM+ sensor, which provides accurate glucose readings for 15 days without finger-stick calibration. This breakthrough aims to lower costs and enhance accessibility in diabetes management. The company is positioned to capitalize on the growing CGM market, projected to reach $28 billion by 2030.
Read more →TRIBTrinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market
Trinity Biotech has launched CGM+, a next-generation AI-native continuous glucose monitoring system designed for the expanding AI wearables market. This innovative device combines glucose monitoring with additional health metrics like heart activity and body temperature. The company aims to position itself at the forefront of intelligent wearables, with a commercial launch expected in mid-2026, opening new revenue opportunities.
Read more →TRIBTrinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround
Trinity Biotech has announced that it has reached a significant profitability inflection point, projecting Adjusted EBITDA-positive operations starting in Q2 2025. The company anticipates being cash flow positive from ongoing activities beginning Q3 2025. This achievement is part of its comprehensive transformation strategy aimed at enhancing financial stability and growth.
Read more →Competitive Position
How TRIB ranks across every disease it competes inCompetitive Position is a premium feature
See how TRIB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial